US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback